Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
filingDate |
2007-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99398420fa92788a5bb9ad238a1a0851 |
publicationDate |
2009-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2009253616-A1 |
titleOfInvention |
Combination therapy for the treatment of cancer |
abstract |
A combination comprising an aurora kinase inhibitor and an efflux transporter inhibitor wherein the aurora kinase inhibitor is a compound of formula (I) or pharmaceutically acceptable salt thereof for use in the treatment of hyperproliferative diseases such as cancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10864280-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10292988-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9566346-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009215770-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018193355-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10653705-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015366979-A1 |
priorityDate |
2006-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |